Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q2

3151.TEDINET S100PL90
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥289.4bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥577.2bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥285.2bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥730m2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥934m2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥2.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.4bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥2.4bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥2.3bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.5bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥1.5bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥316.4bnat 2022-09-30Cons.Assets
Total assets¥313.0bnat 2022-03-31Cons.Assets
Total assets¥327.3bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥212.8bnat 2022-09-30Cons.Liabilities
Total liabilities¥213.0bnat 2022-03-31Cons.Liabilities
Net assets / equity¥103.6bnat 2022-09-30Cons.Net assets
Net assets / equity¥100.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥105.6bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥27.4bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥27.0bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥23.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥23.2bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥27.4bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.3bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥4.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥7.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥2.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥2.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥8.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥27.422022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.42022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥87.882021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥25.672021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥14.012021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio32.4%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.0%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥3.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥146m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥6.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥6.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥58m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2022-04-01 → 2022-09-30¥278.2bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2022-04-01 → 2022-09-30¥273.0bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2022-04-01 → 2022-09-30¥607m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥32m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥178m
—segment totalrevenue2022-04-01 → 2022-09-30¥292.5bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥287.4bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥819m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥295.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥289.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥672m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥3.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30−¥97m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥5.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥5.5bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30¥19m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2021-04-01 → 2021-09-30¥273.4bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2021-04-01 → 2021-09-30¥269.1bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥4.3bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2021-04-01 → 2021-09-30¥739m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥83m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥5.1bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥5.1bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥189m
—segment totalrevenue2021-04-01 → 2021-09-30¥287.6bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥283.3bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥4.3bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥290.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥285.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥915m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 549
ItemContextValueUnit
Other nclPrior1YearInstant12265000000JPY
Other nclCurrentQuarterInstant13468000000JPY
Noncurrent liabilitiesPrior1YearInstant22898000000JPY
Noncurrent liabilitiesCurrentQuarterInstant21573000000JPY
LiabilitiesPrior1YearInstant212991000000JPY
LiabilitiesCurrentQuarterInstant212803000000JPY
Capital stockPrior1YearInstant5000000000JPY
Capital stockCurrentQuarterInstant5000000000JPY
Capital surplusPrior1YearInstant12810000000JPY
Capital surplusCurrentQuarterInstant12810000000JPY
Retained earningsPrior1YearInstant64402000000JPY
Retained earningsCurrentQuarterInstant65096000000JPY
Treasury stockPrior1YearInstant-6581000000JPY
Treasury stockCurrentQuarterInstant-7575000000JPY
Shareholders equityPrior1YearInstant75631000000JPY
Shareholders equityCurrentQuarterInstant75332000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant21645000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant25666000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1683000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant1504000000JPY
Valuation and translation adjustmentsPrior1YearInstant23329000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant27170000000JPY
Non controlling interestsPrior1YearInstant1080000000JPY
Non controlling interestsCurrentQuarterInstant1126000000JPY
Net assetsPrior1YearInstant100041000000JPY
Net assetsCurrentQuarterInstant103628000000JPY
Liabilities and net assetsPrior1YearInstant313033000000JPY
Liabilities and net assetsCurrentQuarterInstant316432000000JPY
Net salesPrior1YTDDuration285229000000JPY
Net salesCurrentYTDDuration289376000000JPY
Cost of salesPrior1YTDDuration264276000000JPY
Cost of salesCurrentYTDDuration267227000000JPY
Gross profitPrior1YTDDuration20953000000JPY
Gross profitCurrentYTDDuration22149000000JPY
Gross profit net gpPrior1YTDDuration20953000000JPY
Gross profit net gpCurrentYTDDuration22149000000JPY
Selling general and administrative expensesPrior1YTDDuration20018000000JPY
Selling general and administrative expensesCurrentYTDDuration21418000000JPY
Operating incomePrior1YTDDuration934000000JPY
Operating incomeCurrentYTDDuration730000000JPY
Interest income noiPrior1YTDDuration24000000JPY
Interest income noiCurrentYTDDuration35000000JPY
Dividends income noiPrior1YTDDuration409000000JPY
Dividends income noiCurrentYTDDuration384000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration14000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration27000000JPY
Office work fee noiPrior1YTDDuration765000000JPY
Office work fee noiCurrentYTDDuration790000000JPY
Other noiPrior1YTDDuration319000000JPY
Other noiCurrentYTDDuration556000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass